# Proteolix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteolix

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Total disclosed funding: $142M
- Latest round: Series C (Sep 8, 2008)
- Investors on record: 7

## About

Proteolix is engaged in the discovery and development of novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases.

## Funding rounds

- Series C, Sep 8, 2008, $79M — Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, US Venture Partners, Vertical Group, Phase4 Partners, Westfield Capital Management
- Series B, May 21, 2007, $23M — Advanced Technology Ventures
- Series B, May 31, 2006, $23M — Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, US Venture Partners, Vertical Group
- Series A, Dec 1, 2003, $18M — Advanced Technology Ventures, Latterell Venture Partners, US Venture Partners, Vertical Group

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series C
- Latterell Venture Partners (https://capitalatlas.ai/funds/latterell-venture-partners) — Series A, Series B, Series C
- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B, Series C
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series A, Series B, Series C
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B, Series C
- Phase4 Partners (https://capitalatlas.ai/funds/phase4-partners) — Series C
- Westfield Capital Management (https://capitalatlas.ai/funds/westfield-capital-management) — Series C